Amarillo Biosciences (NASDAQ:AMAR) is an early stage
bio-technology company engaged in developing biologics
for the treatment of human and animal diseases. AMAR
made an initial public offering of 2.3 million shares
of stock in August. The company is currently focusing
its research on human health indications for the use
of low dose orally delivered natural interferon alpha.
Particularly for the treatment of Sjogren's syndrome,
oral musositis in cancer patients and hepatitis B and C.
A large worldwide market exists for the low dose oral
natural interferon as an inexpensive, non-toxic,
efficacious treatment for disease.
The company owns or licenses 11 United States patents
relating to low dose oral natural interferon. AMAR is also
testing oral interferon in cats with herpesvirus-1 infection,
dogs with keratoconjunctivitis sicca and cattle with
shipping fever or mastitis. The company has filed
investigational new animal drug notices which are now
in effect, for these and other indications, in animals.
AMAR is rather closely held by the following:
Hayashibara Biochemical Laboratories Inc. holds a 24.1
percent stake or 1,232,856 common shares. Hayashibara
manufactures and supplies oral interferon alpha exclusively
to AMAR for human applications outside Japan and animal
applications worldwide.
Mochida Pharmaceutical Co Ltd holds a 5.9 percent stake
or 300,000 common shares. Mochida is a Japanese corporation
in the business of developing and marketing ethical drugs,
diagnostic reagents, skin care products and medical
electronics and equipment.
Joseph Cummins, a Texas investor holds a 13.6 percent stake
or 696,804 common shares.
Announcements are anticipated in the coming months regarding
trial results of AMAR's products. |
